Kotak, which sees 2.4% growth in topline, also forecasts 12% YoY growth for India

Dr. Reddy’s Lab Q3 PAT seen up 60.6% YoY to Rs. 472.4 cr: Sharekhan

Net Sales are expected to increase by 1.9 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs. 3,905 crore, according to Sharekhan.

Dr. Reddys Q3 PAT seen up 37.7% YoY to Rs. 416.9 cr: ICICI Direct

Net Sales are expected to increase by 4.7 percent Y-o-Y (up 5.2 percent Q-o-Q) to Rs. 4,015.2 crore, according to ICICI Direct.

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

Dr Reddy’s Q2 review: Brokerages term results to be in line with estimates; Citi rises target to Rs 2,680

The pharma major reported a rise of 77 percent (year-on-year) in its net profit at Rs 503.8 crore. The company had reported a profit of Rs 284.9 crore during the same period of last year.

Dr Reddy’s Q2 preview: Brokerages expect subdued show, profit likely around Rs 330-370 cr

The effect of Suboxone based on US court order is likely to weigh as well.

Dr. Reddy’s Labs Q2 PAT seen up 32% YoY to Rs. 380 cr: HDFC Securities

Net Sales are expected to increase by 10.8 percent Y-o-Y (up 5.6 percent Q-o-Q) to Rs. 3,930 crore, according to HDFC Securities.

Dr. Reddy’s Lab Q2 PAT seen up 20.2% YoY to Rs. 356.1 cr: Sharekhan

Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.4 percent Q-o-Q) to Rs. 3,750 crore, according to Sharekhan.

Dr. Reddys Q2 PAT seen up 18.2% YoY to Rs. 361.1 cr: ICICI Direct

Net Sales are expected to increase by 8.4 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs. 3,857.7 crore, according to ICICI Direct.

Dr Reddy’s Laboratories Q1 PAT seen up 421.7% YoY to Rs. 308.3 cr: Kotak

Net Sales are expected to increase by 9.7 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 3,638.8 crore, according to Kotak.

Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

"For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

Dr. Reddy’s Lab Q4 PAT may dip 17.7% YoY to Rs. 269.4 cr: KR Choksey

Net Sales are expected to increase by 11.1 percent Y-o-Y (down 3.7 percent Q-o-Q) to Rs. 3,663.7 crore, according to KR Choksey.

Dr. Reddy’s Labs Q4 PAT may dip 4.8% YoY to Rs. 300 cr: HDFC Securities

Net Sales are expected to increase by 1 percent Y-o-Y (down 5.7 percent Q-o-Q) to Rs. 3,590 crore, according to HDFC Securities.

Dr Reddy's Q4 PAT may dip 16.7% YoY to Rs. 268.4 cr: Edelweiss

Net Sales are expected to decrease by 3.7 percent Y-o-Y (down 10.1 percent Q-o-Q) to Rs. 3,421.2 crore, according to Edelweiss.

Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

Hope to resolve Srikakulam with US FDA soon, says DRL

From the pharmaceutical space, Dr Reddys Laboratories (DRL) reported a mixed set of earnings this quarter. In an interview to CNBC-TV18, Saumen Chakraborty, CFO of DRL discussed the company's Q3 performance.

Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

Weak US sales, INR appreciation to drag earnings; Dr Reddy, Cadila top pick: Edelweiss

The USFDA granted 246 nods in Q3FY18, which is the highest-ever approvals in a single quarter. Cadila Healthcare received 23 and Aurobindo Pharma got 18 approvals.

Dr Reddys Labs Q2 profit seen down 9% on continued pricing pressure in US

Consolidated revenue during the quarter is seen rising 3 percent year-on-year to Rs 3,684 crore due to restocking post GST, according to average of estimates of analysts polled by CNBC-TV18.

Dr Reddys Labs Q2 PAT seen up 4.7% YoY to Rs. 308.8 cr: Kotak

Net Sales are expected to increase by 5.6 percent Y-o-Y (up 14.2 percent Q-o-Q) to Rs. 3787.8 crore, according to Kotak.

Nifty earnings broadly resilient amid margin pain, GST hits smaller companies

Expectations were running low on account of pre-GST implementation adjustments in the quarter, and overall, the Nifty earnings have not resulted in any incremental negative surprise.

Have buy rating on Glenmark Pharma: HDFC Securities

In an interview to CNBC-TV18, Amey Chalke of HDFC Securities spoke about Q1 FY18 earnings from pharma sector.

Dr Reddy's Labs Q1 profit growth may be over 2-fold on strong operational numbers

Revenue is seen rising 4.6 percent year-on-year to Rs 3,383 crore in June quarter, according to average of estimates of analysts polled by CNBC-TV18.

Expect to see 18-20% growth for FY18: TCI Express

In an interview to CNBC-TV18, Chander Agarwal, MD & CEO, TCI Express spoke about the results and his outlook for the company.

Dr Reddy's Labs Q4: Analysts see hope in US biz recovery, reduced regulatory concerns

Brokerages largely remain optimistic about the pharma major’s improvement in US business as well as reduced regulatory risks, while some also highlight the seriousness of US FDA’s observations at some of its plants.